477541-28-9Relevant academic research and scientific papers
Aleglitazar, a new, potent, and balanced dual PPARα/γ agonist for the treatment of type II diabetes
Benardeau, Agnes,Benz, Joerg,Binggeli, Alfred,Blum, Denise,Boehringer, Markus,Grether, Uwe,Hilpert, Hans,Kuhn, Bernd,Maerki, Hans Peter,Meyer, Markus,Puentener, Kurt,Raab, Susanne,Ruf, Armin,Schlatter, Daniel,Mohr, Peter
scheme or table, p. 2468 - 2473 (2010/03/24)
Design, synthesis, and SAR of novel α-alkoxy-β-arylpropionic acids as potent and balanced PPARαγ coagonists are described. One representative thereof, Aleglitazar ((S)-2Aa), was chosen for clinical development. Its X-ray structure in complex with both receptors as well as its high efficacy in animal models of T2D and dyslipidemia are also presented.
NOVEL HETEROCYCLIC DERIVATIVES AND MEDICINAL USE THEREOF
-
Page 26, (2010/02/05)
The novel heterocyclic derivative of the present invention is a novel heterocyclic derivative having the formula (I') wherein R1 is a hydrogen atom or C1-6 alkyl, R2 is -CO-C(R4)=C(R4)-R5 w
